Extended safety tracking for mast cell disorder drug
NCT ID NCT06748001
Summary
This study continues monitoring the safety of avapritinib for people with systemic mastocytosis who previously participated in related trials and are still benefiting from the medication. It tracks side effects and safety issues over a longer period. The goal is to better understand the long-term safety profile of this treatment for this rare condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASTOCYTOSIS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno
RECRUITINGSalerno, 84131, Italy
-
Erasmus Medisch Centrum
RECRUITINGRotterdam, 3015, Netherlands
-
Guys and St Thomas NHS Foundation Trust - St Thomas Hospital
RECRUITINGLondon, SE19RT, United Kingdom
-
Oslo University Hospital
RECRUITINGOslo, 0424, Norway
-
The Hospital for Sick Children
RECRUITINGToronto, Ontario, M5G 1X8, Canada
-
Universitair Medisch Centrum Groningen
RECRUITINGGroningen, 9700, Netherlands
-
Universitair Ziekenhuis Antwerpen (UZA)
RECRUITINGEdegem, 2650, Belgium
Conditions
Explore the condition pages connected to this study.